Payment overview · 2025
General Payments
$338.53
14 reported records · 7 companies
Healthcare provider profile · identity verified
Lucy Green Davis, MD
Allopathic & Osteopathic Physicians|Family Medicine · DANIEL ISLAND, SC · NPI 1427015171
Verified facts
What the public records show
CMS Open Payments records show Lucy Green Davis, MD received $338.53 in general payments during 2025 across 14 reported records.
ABBVIE INC. accounted for 32.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $110.83 | 32.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.43 | 18.4% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $54.80 | 16.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $40.34 | 11.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.48 | 7.2% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.08 | 6.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.57 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $338.53 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.03 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.43 | 3 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $54.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $40.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 467 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 221 | 56 |
| Omeprazole | Omeprazole | 192 | 53 |
| Losartan Potassium | Losartan Potassium | 174 | 46 |
| Trazodone Hcl | Trazodone Hcl | 171 | 41 |
| Lisinopril | Lisinopril | 166 | 54 |
| Valsartan | Valsartan | 157 | 44 |
| Alprazolam | Alprazolam | 128 | 31 |
| Simvastatin | Simvastatin | 122 | 33 |
| Metformin Hcl Er | Metformin Hcl | 120 | 37 |
| Gabapentin | Gabapentin | 117 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 28 |
| Alendronate Sodium | Alendronate Sodium | 91 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 14 |
| Metformin Hcl | Metformin Hcl | 76 | 23 |
| Ozempic | Semaglutide | 76 | 16 |
| Sertraline Hcl | Sertraline Hcl | 75 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 23 |
| Eliquis | Apixaban | 71 | 15 |
| Bupropion Xl | Bupropion Hcl | 69 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 35 |
| Montelukast Sodium | Montelukast Sodium | 61 | 15 |
| Ezetimibe | Ezetimibe | 57 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 16 |
| Glipizide Er | Glipizide | 56 | 13 |
| Lorazepam | Lorazepam | 56 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 14 |
| Famotidine | Famotidine | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Synthroid | Levothyroxine Sodium | 46 | 14 |
| Celecoxib | Celecoxib | 42 | 14 |
| Meloxicam | Meloxicam | 41 | 12 |
| Allopurinol | Allopurinol | 40 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 11 |
| Estradiol | Estradiol | 36 | 12 |
| Atenolol | Atenolol | 35 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Furosemide | Furosemide | 27 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | 14 |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Mupirocin | Mupirocin | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $338.53 · 14 records | ABBVIE INC. | Ambulatory Monitoring & Diagnostics Undivided, Cologuard Collection Kit, ELIQUIS, FLOWTRIEVER, NURTEC ODT, PAXLOVID, QULIPTA, SAPIEN 3 Ultra RESILIA, UBRELVY, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error